| Literature DB >> 20234363 |
B Gagnon1, M Abrahamowicz, Y Xiao, M-E Beauchamp, N MacDonald, G Kasymjanova, H Kreisman, D Small.
Abstract
BACKGROUND: C-reactive protein (CRP) is gaining credibility as a prognostic factor in different cancers. Cox's proportional hazard (PH) model is usually used to assess prognostic factors. However, this model imposes a priori assumptions, which are rarely tested, that (1) the hazard ratio associated with each prognostic factor remains constant across the follow-up (PH assumption) and (2) the relationship between a continuous predictor and the logarithm of the mortality hazard is linear (linearity assumption).Entities:
Mesh:
Substances:
Year: 2010 PMID: 20234363 PMCID: PMC2853092 DOI: 10.1038/sj.bjc.6605603
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Patients’ characteristics (N=269)a
|
|
|
|---|---|
| Age: mean (s.d.) | 64.3 (11.0) |
| Sex: female | 136 (50.6) |
| Stage: IIIA/IIIB | 70 (26.0) |
| IIIB+pleural effusion/IV | 199 (74.0) |
| ECOG | |
| 0–1 | 213 (79.2) |
| 2 | 56 (20.8) |
| Smoking status: Never | 41 (15.2) |
| Ever | 228 (84.8) |
| Chemotherapy type: | |
| Single-agent | 66 (24.5) |
| Double-agent | 203 (75.5) |
| Pathology: | |
| Adenocarcinoma | 177 (65.8) |
| Large cell carcinoma | 22 (8.2) |
| Squamous cell carcinoma | 32 (11.9) |
| Undifferentiated carcinoma | 38 (14.1) |
| CRP | |
| Mean (s.d.) | 36.2 (53.6) |
| Median {quartile} (range) | 13.1 {4.9, 39.9} (0.3, 316.8) |
| Log2 CRP: | |
| Mean (s.d.) | 3.8 (2.2) |
| Median {quartile} (range) | 3.7 {2.3, 5.3} (−1.7, 8.3) |
| Albumin | |
| Mean (s.d.) | 40.2 (4.1) |
| LDH | |
| Mean (s.d.) | 248.8 (199.4) |
| Median {quartile} (range) | 211 {169, 263} (98, 2500) |
| Log2 LDH: | |
| Mean (s.d.) | 7.8 (0.6) |
| Median {quartile} (range) | 7.7 {7.4, 8.0} (6.6, 11.3) |
| Calcium | 2.35 (0.19) |
| Alkaline phosphatase | 104.2 (59.2) |
| Haemoglobin | 130.2 (17.1) |
| Platelet | 326.7 (117.2) |
| Neutrophil counts | 7.09 (3.55) |
| Lymphocytes | 1.59 (0.70) |
| Percentage of weight loss: mean (s.d.) | 4.9 (6.6) |
Abbreviations: CRP=C-reactive protein; LDH=lactate dehydrogenase.
N=269 for all variables except for calcium for which N=264.
Eastern cooperative oncology group.
All include platinum-based chemotherapy.
Normal values: CRP ⩽10 mg l–1; albumin 35–52 g l–1; LDH 110–210 U l–1; calcium 2.12–2.62 mmol l–1; alkaline phosphatase 56–120 U l–1; haemoglobin 140–180 g l–1; platelet 140–440 × 109 l–1; neutrophil counts 1.60–7.70 × 109 l–1; and lymphocytes 0.80–4.40 × 109 l–1.
Figure 1Flowchart of multivariable models building.
spline
-based models, either the PH or the linearity assumptions were violated (P<0.05 for the respective test) for several variables.Results of univariate Cox's PH models (N=269)a
|
|
|
|
|
|
|---|---|---|---|---|
| Age | 1.009 (0.996, 1.021) | 0.180 | 0.119 | 0.268 |
| Sex: (male | 1.458 (1.109, 1.917) | 0.007 | 0.817 | N/A |
| Stage: (IIIB+pleural effusion/4 | 2.031 (1.454, 2.837) | <0.001 | 0.426 | N/A |
| ECOG | 2.034 (1.488, 2.782) | <0.001 | 0.047 | N/A |
| Smoking status: (ever | 1.934 (1.278, 2.927) | 0.002 | 0.253 | N/A |
| Chemotherapy type: (single | 1.845 (1.353, 2.515) | <0.001 | 0.153 | N/A |
| Pathology: adenocarcinoma | Ref | Ref | Ref | N/A |
| Large cell carcinoma | 1.072 (0.670, 1.716) | 0.771 | 0.124 | |
| Squamous cell carcinoma | 0.934 (0.611, 1.428) | 0.753 | 0.610 | |
| Undifferentiated carcinoma | 1.283 (0.858, 1.917) | 0.225 | 0.193 | |
| Log2 CRP: (per doubling of CRP values) | 1.175 (1.102, 1.252) | <0.001 | 0.002 | 0.078 |
| Albumin: (per ↓ | 1.098 (1.061, 1.136) | <0.001 | <0.001 | 0.190 |
| Log2 LDH: (per doubling of LDH values) | 2.336 (1.877, 2.909) | <0.001 | 0.130 | 0.093 |
| Calcium: (per ↑ | 2.025 (0.897, 4.571) | 0.089 | 0.533 | 0.137 |
| Alkaline phosphatase: (per ↑ of 10 U l–1) | 1.044 (1.020, 1.068) | <0.001 | 0.443 | 0.930 |
| Haemoglobin: (per ↓ of 10 g l–1) | 1.094 (1.009, 1.186) | 0.030 | 0.087 | 0.394 |
| Platelet: (per ↑ of 10 × 109 l–1) | 1.011 (0.999, 1.023) | 0.063 | 0.044 | 0.623 |
| Neutrophil counts: (per ↑ of 1 × 109 l–1) | 1.117 (1.071, 1.164) | <0.001 | 0.010 | 0.030 |
| Lymphocytes: (per ↓ of 1 × 109 l–1) | 1.490 (1.214, 1.829) | <0.001 | 0.132 | 0.702 |
| Percentage of weight loss: (per ↓ of 1%) | 1.020 (1.000, 1.041) | 0.049 | 0.157 | 0.204 |
Abbreviations: CRP=C-reactive protein; LDH=lactate dehydrogenase; PH=proportional hazard.
N/A: the test of linearity is not applicable to categorical covariates.
N=269 for all variables except for calcium for which N=264.
Unadjusted hazard ratio (HR) and 95% confidence interval (95% CI).
Eastern cooperative oncology group.
↓: decrease.
↑: increase.
Results of the multivariable Cox's PH model (N=269)
|
|
|
|
|
|
|---|---|---|---|---|
| Stage: (IIIB+pleural effusion/4 | 1.815 (1.268, 2.597) | 0.001 | 0.204 | N/A |
| ECOG | 1.348 (0.958, 1.896) | 0.086 | 0.165 | N/A |
| Smoking status: (ever | 2.087 (1.349, 3.230) | 0.001 | 0.135 | N/A |
| Chemotherapy type: (single | 1.539 (1.082, 2.188) | 0.016 | 0.067 | N/A |
| Log2 CRP: (per doubling of CRP values) | 1.108 (1.027, 1.196) | 0.008 | 0.039 | 0.130 |
| Albumin: (per ↓ | 1.015 (0.974, 1.058) | 0.485 | <0.001 | 0.024 |
| Log2 LDH: (per doubling of LDH values) | 2.159 (1.700, 2.742) | <0.001 | 0.636 | 0.590 |
| Alkaline phosphatase: (per ↑ | 1.019 (0.993, 1.047) | 0.150 | 0.075 | 0.034 |
| Neutrophil counts: (per ↑ of 1 × 109 l–1) | 1.082 (1.037, 1.129) | <0.001 | 0.027 | 0.041 |
| Lymphocytes: (per ↓ of 1 × 109 l–1) | 1.307 (1.050, 1.626) | 0.016 | 0.550 | 0.460 |
| Deviance | 1902.2 | |||
| AIC | 1922.2 |
Abbreviations: AIC=Akaike's information criterion; CRP=C-reactive protein; LDH=lactate dehydrogenase; PH=proportional hazard.
N/A: the test of linearity is not applicable to categorical covariates.
Adjusted hazard ratio (HR) and 95% confidence interval (95% CI).
Eastern cooperative oncology group.
↓: decrease.
↑: increase.
Deviance=−2*log-likelihood.
Results of the flexible spline-based model (N=269)
|
|
|
|
|---|---|---|
| Stage: (IIIB+pleural effusion/4 | 1.859 (1.284, 2.691) | <0.001 |
| ECOG | 1.336 (0.923, 1.935) | 0.116 |
| Smoking status: (ever | 2.248 (1.419, 3.561) | <0.001 |
| Chemotherapy type: (single | 1.462 (0.990, 2.160) | 0.041 |
| Log2 CRP: (per doubling of CRP values) | * | 0.003 (overall |
| Albumin: (per ↓ | ** | 0.001 (overall |
| Log2 LDH: (per doubling of LDH values) | 2.281 (1.661, 3.142) | <0.001 |
| Alkaline phosphatase: (per ↑of 10 U l–1) | 1.012 (0.980, 1.041) | 0.366 |
| Neutrophil counts: (per ↑ | 1.072 (1.025, 1.122) | 0.001 |
| Lymphocytes: (per ↓ of 1 × 109 l–1) | 1.313 (1.035, 1.666) | 0.012 |
| Deviance | 1873.3 | |
| AIC | 1909.3 |
Abbreviations: AIC=Akaike's information criterion; CRP=C-reactive protein; LDH=lactate dehydrogenase.
Adjusted hazard ratio (HR) and 95% confidence interval (95% CI).
Eastern cooperative oncology group.
↓: decrease.
↑: increase.
Deviance=−2*log-likelihood.
*Both the time-dependent (P=0.033) and non-linear (P=0.015) effects were significant. The estimated non-linear effects, at selected follow-up times, are shown in Figure 2.
**Both the time-dependent (P=0.0001) and non-linear (P=0.038) effects were significant. The estimated non-linear effects, at selected follow-up times, are shown in Figure 3.
#P-value for a likelihood ratio test, with 5 degrees of freedom, of the null hypothesis of no association, obtained by comparing the deviances of (i) a flexible model where both time-dependent and non-linear effects of a given variable are modeled by splines, vs (ii) a simpler ‘reduced’ model, which does not include the variable being tested (see the section on “Statistical analyses” for details of the test).
Figure 2Results of the Cox's PH and flexible spline-based multivariable modeling of the effect of CRP on survival. The bold line represents the linear estimate from the Cox’s PH model. The curves correspond to the flexible spline estimates at different times from 3 months (t=3) to 18 months (t=18) after the initiation of chemotherapy. Each curve shows how the adjusted hazard ratio at the corresponding time, relative to the value of 4 mg l−1, changes with increasing value of C-reactive protein.
Figure 3Results of the Cox's PH and flexible spline-based multivariable modeling of the effect of albumin on survival. The bold line represents the linear estimate from the Cox’s PH model. The curves correspond to the flexible spline estimates at different times from 3 months (t=3) to 9 months (t=9) after the initiation of chemotherapy. Each curve shows how the adjusted hazard ratio at the corresponding time, relative to the value of 40 mg l−1, changes with decreasing value of albumin.